SCHEMBL851979

SCHEMBL851979

N#Cc1ccc(Oc2cc(Oc3ccc(C#N)cc3)cc(C(=O)O)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 2/20 0.62
PARP10 Q53GL7 2/20 0.62
PARP2 Q9UGN5 1/20 0.62
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
MAPT P10636 2/20 0.56
KDM4E B2RXH2 2/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 1/20 0.56
PKM P14618 1/20 0.56
MAPK1 P28482 1/20 0.56
RAB9A P51151 1/20 0.56
IL18 Q14116 1/20 0.56
AKR1C3 P42330 1/20 0.49
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MMP2 P08253 1/20 0.45
SRD5A2 P31213 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL851606 0.90 PARP15 (0.55) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL505264 0.89 PARP15 (0.71) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL851678 0.87 MEN1 (0.60) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL851240 0.86 FFAR1 (0.55) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL850692 0.85 PARP15 (0.53) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL13268612 0.85 AKR1C3 (0.72) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL29582194 0.84 PARP15 (0.57) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL3793720 0.84 PARP10 (0.81) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL28781661 0.83 PARP10 (0.63) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL28060732 0.83 KMT2A (0.66) PARP15PARP10MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140200225-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2014-07-17 US disclosed
US-8722930-B2 Protease inhibitors ORION CORPORATION (FI) 2014-05-13 US disclosed
US-20120136002-A1 PROTEASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-31 US disclosed
EP-2432556-A1 PROTEASE INHIBITORS Orion Corporation (FI) 2012-03-28 EP disclosed
WO-2010133748-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200225-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 PARP15 118/4885PARP10 309/4885PARP2 768/4885
US-20120136002-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 PARP15 118/4885PARP10 309/4885PARP2 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.